SamuelAFuntMD

PubMed

• Extramammary Paget Disease. Part II. Evidence-based Approach to Management.
  Rohan R Shah, Kalee Shah, Britney N Wilson, Sharif Hosein, Mirabel Dafinone, Mario M Leitao, Jan Smogorzewski, Christopher Crane, Samuel A Funt, Anthony Rossi> ;Journal of the American Academy of Dermatology. 2024 Apr 6
• Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
  Samuel A Funt, Andrea Knezevic, Kaamilah Wilson, Maria Bromberg, Amy Budnick, Kerri L O'Connor, Deaglan J McHugh, Erik Larsen, Dean F Bajorin, Robert J Motzer, Emily S...> ;Cancer. 2023 Dec 15
• 2 citations
  Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
  Brendan J Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A Funt, Chung-Han Lee, David H Aggen, Ashley M Regazzi, Ziyu Chen, Michael Lattanzi, ...> ;Clinical Cancer Research. 2023 Nov 14
• Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum.
  Richard S Matulewicz, Nicole Benfante, Samuel A Funt, Darren R Feldman, Brett Carver, Alexander Doudt, Andrea Knezevic, Joel Sheinfeld> ;The Journal of Urology. 2024 Jan 1
• 2 citations
  Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
  Rami S Vanguri, James W Smithy, Yanyun Li, Mingqiang Zhuang, Colleen A Maher, Nathaniel Aleynick, Xiyu Peng, Hikmat Al-Ahmadie, Samuel A Funt, Jonathan E Rosenberg, Go...> ;The Journal of Pathology. 2023 Nov 1
• 2 citations
  TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
  Siri Amanda Tvingsholm, Marcus Svensson Frej, Vibeke Mindahl Rafa, Ulla Kring Hansen, Maria Ormhøj, Alexander Tyron, Agnete W P Jensen, Mohammad Kadivar, Amalie Kai Be...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
• 2 citations
  Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot Study.
  Michael A Hoyt, Ashley Wei-Ting Wang, Raymond Carrillo Ceja, Jennifer S Cheavens, Michael A Daneshvar, Darren R Feldman, Samuel A Funt, Christian J Nelson> ;Annals of Behavioral Medicine. 2023 Aug 21
• 4 citations
  Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
  Mahdi Golkaram, Samuel A Funt, Hikmat Al-Ahmadie, Shannon Kaplan, Fan Song, Ashley Regazzi, Vladimir Makarov, Fengshen Kuo, Irina Ostrovnaya, Venkatraman Seshan, Chen ...> ;Journal of Clinical Oncology. 2023 Jun 10
• 2 citations
  Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
  Ying L Liu, Beryl L Manning-Geist, Andrea Knezevic, Luxue Deng, Maria Bromberg, Samuel A Funt, Jane L Meisel, Oliver Zivanovic, Kara Long Roche, Yukio Sonoda, Ginger J...> ;Gynecologic Oncology. 2023 Mar 1
• Evaluation of Women With a Positive Urine Cytology and no Demonstrable Disease in the Urinary Tract.
  Sherri M Donat, Yukio Sonoda, Hikmat Al-Ahmadie, Rajmohan Murali, Dianna L Ng, Samuel A Funt, Kay J Park> ;Urology. 2023 Mar 1
• 1 citations
  Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.
  Joshua I Warrick, Wenhuo Hu, Hironobu Yamashita, Vonn Walter, Lauren Shuman, Jenna M Craig, Lan L Gellert, Mauro A A Castro, A Gordon Robertson, Fengshen Kuo, Irina Os...> ;Nature Communications. 2022 Dec 23
• 9 citations
  FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.
  Joshua I Warrick, Wenhuo Hu, Hironobu Yamashita, Vonn Walter, Lauren Shuman, Jenna M Craig, Lan L Gellert, Mauro A A Castro, A Gordon Robertson, Fengshen Kuo, Irina Os...> ;Nature Communications. 2022 Nov 2
• 8 citations
  A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors.
  Nabil Adra, David J Vaughn, Lawrence H Einhorn, Nasser H Hanna, Samuel A Funt, Matt Rosales, Ahsan Arozullah, Darren R Feldman> ;Investigational New Drugs. 2022 Oct 1
• 31 citations
  PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.
  Ramin Sedaghat Herati, David A Knorr, Laura A Vella, Luisa Victoria Silva, Lakshmi Chilukuri, Sokratis A Apostolidis, Alexander C Huang, Alexander Muselman, Sasikanth ...> ;Nature Immunology. 2022 Aug 1
• 5 citations
  Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Se...
  Fei Ye, Darren R Feldman, Alisa Valentino, Rachel So, Maria Bromberg, Shah Khan, Samuel A Funt, Joel Sheinfeld, David B Solit, Melissa S Pessin, Ellinor I Peerschke> ;The Journal of Molecular Diagnostics. 2022 Aug 1
• 4 citations
  Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
  Nima Almassi, Karissa Whiting, Antoun Toubaji, Andrew T Lenis, Emmet J Jordan, Helen Won, Ashley M Regazzi, Ying-Bei Chen, Anuradha Gopalan, Sahussapont J Sirintrapun,...> ;JCO Precision Oncology. 2022 Jun 1
• 18 citations
  Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
  Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z., de Andrade, K., Bajorin, D., Bandlamudi, C., Callahan, M., Funt, S., Hadrup, S., Holm, J., Rosenberg, J., Shah, S., ...> ;Nature. 2022 Jun 1
• 1 citations
  Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
  Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z., de Andrade, K., Bajorin, D., Bandlamudi, C., Callahan, M., Funt, S., Hadrup, S., Holm, J., Rosenberg, J., Shah, S., ...> ;Nature. 2022 Jun 1
• Reply to S. Zhang.
  Michael Lattanzi, Samuel A Funt, Jonathan E Rosenberg> ;Journal of Clinical Oncology. 2022 Aug 10
• 6 citations
  Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.
  Min Yuen Teo, Brendan J Guercio, Arshi Arora, Xueli Hao, Ashley M Regazzi, Timothy Donahue, Harry W Herr, Alvin C Goh, Eugene K Cha, Eugene Pietzak, Sherri M Donat, Gu...> ;Clinical Genitourinary Cancer. 2022 Oct 1
• 1 citations
  Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
  Min Yuen Teo, Hikmat Al-Ahmadie, Kenneth Seier, Christopher Tully, Ashley M Regazzi, Eugene Pietzak, David B Solit, Satish Tickoo, Victor Reuter, Eugene K Cha, Harry H...> ;British Journal of Cancer. 2022 May 1
• 25 citations
  Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
  Samuel A Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan, Min Yuen Teo, Chung-Han Lee, David Aggen, Danielle Zimmerman, Deaglan McHugh, Arl...> ;Journal of Clinical Oncology. 2022 Apr 20
• 34 citations
  Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
  Jeppe Sejerø Holm, Samuel A Funt, Annie Borch, Kamilla Kjærgaard Munk, Anne-Mette Bjerregaard, James L Reading, Colleen Maher, Ashley Regazzi, Phillip Wong, Hikmat Al-...> ;Nature Communications. 2022 Apr 11
• 48 citations
  LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
  , , , , , , , , , , , , , , , , , , , , , , > ;Science Translational Medicine. 2021 Aug 25
• 11 citations
  Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors.
  Jose Mauricio Mota, Min Yuen Teo, Karissa Whiting, Han A Li, Ashely M Regazzi, Chung-Han Lee, Samuel Funt, Dean F. Bajorin, Irina Ostrovnaya, Gopa Iyer, Jonathan E. Ro...> ;Journal of Immunotherapy. 2021 Jun 3
• Join now to see all

Lectures

• A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018